CCRM

@CCRM_ca

CCRM supports the development & commercialization of regenerative medicines & associated enabling technologies, with a specific focus on cell & gene therapy.

Toronto
Vrijeme pridruživanja: lipanj 2011.

Tweetovi

Blokirali ste korisnika/cu @CCRM_ca

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CCRM_ca

  1. Prikvačeni tweet
    13. lis 2017.

    A little teaser for CCRM's corporate video. You can find the full video on our website's homepage

    Poništi
  2. proslijedio/la je Tweet

    The 2020 global performance report is here! 🇨🇦 leap frogs Japan to move into #2 on the list with a score of 9.9 out of 10 according to . Ontario is .

    Poništi
  3. 4. velj

    CCRM and recently hosted a and event with local and international speakers. Here are videos of the talks if you were unable to join in person or by webinar

    , , i još njih 4
    Poništi
  4. proslijedio/la je Tweet
    3. velj
    Poništi
  5. proslijedio/la je Tweet
    3. velj

    AUD $14.7 million of funding has been given to researches at including and to see if stem cell therapy can be used to treat brain damage caused by preterm birth. READ MORE:

    Poništi
  6. proslijedio/la je Tweet
    4. velj

    Are you a PhD student or post-doc working in and interested in translation and commercialization? Join us in this June for Summer by Design. Apply by Feb. 21 at . In partnership with .

    Poništi
  7. proslijedio/la je Tweet
    3. velj

    Catalent chief John Chiminski triggers a $315M-plus wager on the booming cell therapy market now in the making

    Poništi
  8. proslijedio/la je Tweet
    3. velj

    How much does it cost to bootstrap a gene therapy startup? Not too much if you're Jim Wilson, per Passage Bio's $125M IPO filing

    Poništi
  9. 3. velj

    Thank you for sharing your thoughts on this Dr. Till. Please read.

    Poništi
  10. proslijedio/la je Tweet
    31. sij

    We are now accepting applications for Summer by Design, our 2-week workshop for PhD candidates & post-docs on translating and commercializing research. Apply by Feb. 21: . In partnership with .

    , , i još njih 7
    Poništi
  11. 31. sij

    Congratulations on your appointment as the new CEO, Matthew Durdy. CCRM looks forward to continued good relations and collaborations in the future. Best wishes to Kevin Thompson in his new pursuits. He has much to be proud of.

    Poništi
  12. proslijedio/la je Tweet
    31. sij

    Looks like a very useful article on the development of therapies with a focus on the challenges encountered navigating the regulatory process in Europe and an update on their performance after approval.

    Poništi
  13. 31. sij

    Our latest blog post is all about understanding reprogramming to generate iPSCs and how to get them ready.

    Poništi
  14. 31. sij

    Last day to show how has influenced your research Here is one more reason why CCRM 💙 for

    , , i još njih 2
    Poništi
  15. proslijedio/la je Tweet

    Biomedical Engineers at are learning to shape patient health and healthcare both now and for the future. Watch the video to find out how:

    Poništi
  16. 30. sij
    Poništi
  17. 30. sij
    Poništi
  18. proslijedio/la je Tweet
    28. sij
    Poništi
  19. proslijedio/la je Tweet
    28. sij

    Biotech millionaire funds free drugs for ultra-rare diseases. So exciting to see positive steps towards cures for those with ultra, ultra rare disorders.

    Poništi
  20. proslijedio/la je Tweet
    29. sij

    Very sad news for the evidence-based treatment of patients and for companies focussed on ethical research. U.S. judge rejects FDA bid to shut down stem cell clinics, dealing blow to regulators

    Poništi
  21. proslijedio/la je Tweet
    29. sij

    Writing in Cell & Gene, details seven trends to follow in the field of and this year.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·